Liver Lineup: Advances, Gaps, and What’s Next in Viral Hepatitis

About this episode

The episode discusses the ongoing challenges in viral hepatitis care despite advancements in treatment.

In this episode of Liver Lineup: Updates and Unfiltered Insights , hosts Nancy Reau, MD, and Kimberly Brown, MD, tackle a paradox that continues to define viral hepatitis care: despite curative therapies for hepatitis C and highly effective suppression for hepatitis B, global and domestic elimination goals remain out of reach. The conversation reframes viral hepatitis not as a “finished” chapter in hepatology, but as an ongoing public health challenge shaped by missed screening, gaps in linkage to care, and uneven adoption of evidence-based interventions. Key episode timestamps: 0:00:00 – Hepatitis elimination gaps; dialysis-unit success; primary-care screening barriers. 0:04:30 – Statins in HBV/HCV: reduced HCC/decompensation; safety in compensated disease. 0:08:41 – GLP‑1 agonists: improved liver outcomes and cancer/cardiometabolic profile; safety concerns addressed. 0:13:21 – HBV functional cure and Bepi: niche role, durability, small but meaningful responder group. 0:19:28 – HBV/HDV: disease severity; new mAb + siRNA regimen; comparison with existing options; access issues. 0:23:28 – Bulevirtide durability data; real‑world compassionate-use case with recompensation and early…

People in this episode

Hosts: Nancy Reau, Kimberly Brown

Topics covered

• viral hepatitis
• hepatitis C
• hepatitis B
• public health
• screening
• linkage to care
• evidence-based interventions

Keywords

• curative therapies
• screening barriers
• statins
• GLP-1 agonists
• HBV functional cure
• Bulevirtide

Mentioned in this episode

Products: statins, GLP-1 agonists, Bulevirtide

Books & works: Liver Lineup: Updates and Unfiltered Insights

More episodes of HCPLive Podcasts

• Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min